Daniil Stroyakovskiy

机构：CI2, City Clinical Hospital, Moscow City Oncology Hospital №62 · ORCID：0000-0003-1973-1092

发表论文 216 篇 · 总被引 24966 次 · h-index 49

代表论文

• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 114)
• Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer (2025 · JAMA Oncology · 被引 22)
• Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02). (2026 · Journal of Clinical Oncology · 被引 3)
• LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes (2025 · Annals of Oncology · 被引 3)
• Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial (2025 · European Journal of Cancer · 被引 3)
• Intermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer (2025 · Journal of Modern Oncology · 被引 1)